Drug Trial Radar · NCT00254046
TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
Last checked: Nov 19, 2026Latest source record: Jun 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
616
Actual
Start
Nov 2005
Primary completion
Feb 2007
Study completion Jul 2008
Sponsor
- Lead sponsor
- Tibotec Pharmaceuticals, IrelandIndustry
- Sponsor type
- Industry
- First posted
- Nov 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus. The study will also investigate whether this new medication is well tolerated, and to further confirm that the medication is safe to be used.
Conditions
- HIV
Interventions
TMC125Drug
2 X100 mg tablets b.i.d.96 weeks
PlaceboDrug
2 tablets b.i.d.96 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen.Time frame: 24 weeks
Locations
55 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Beverly Hills, California
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
New Haven, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Fort Lauderdale, Florida
Site not named
Miami, Florida
Site not named
North Miami Beach, Florida
Site not named
Pensacola, Florida
Site not named
Safety Harbor, Florida
Site not named
Tampa, Florida
Site not named
Vero Beach, Florida
Site not named
Atlanta, Georgia
Site not named
Macon, Georgia
Site not named
Wichita, Kansas
Site not named
Boston, Massachusetts
Site not named
Newark, New Jersey
Site not named
Santa Fe, New Mexico
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Huntersville, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
Galveston, Texas
Site not named
Houston, Texas
Site not named
Longview, Texas
Site not named
Annandale, Virginia
Site not named
Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Neuquén, Argentina
Site not named
San Juan Bautista, Argentina
Site not named
Curitiba, Brazil
Site not named
Rio de Janeiro, Brazil
Site not named
Salvador, Brazil
Site not named
São Paulo, Brazil
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.